Marker Therapeutics, Inc. (MRKR): Price and Financial Metrics


Marker Therapeutics, Inc. (MRKR): $0.34

0.00 (0.81%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MRKR to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

MRKR Stock Price Chart Interactive Chart >

Price chart for MRKR

MRKR Price/Volume Stats

Current price $0.34 52-week high $3.65
Prev. close $0.34 52-week low $0.28
Day low $0.32 Volume 95,300
Day high $0.35 Avg. volume 582,243
50-day MA $0.38 Dividend yield N/A
200-day MA $1.01 Market Cap 28.23M

Marker Therapeutics, Inc. (MRKR) Company Bio


Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.


MRKR Latest News Stream


Event/Time News Detail
Loading, please wait...

MRKR Latest Social Stream


Loading social stream, please wait...

View Full MRKR Social Stream

Latest MRKR News From Around the Web

Below are the latest news stories about Marker Therapeutics Inc that investors may wish to consider to help them evaluate MRKR as an investment opportunity.

Why Are Marker Therapeutics Shares Trading Lower On Thursday?

Marker Therapeutics Inc (NASDAQ: MRKR ) shares are trading lower after Roth Capital downgrades the company from Buy to Neutral and lowers the price target from $3 to $1 . The company reported initial results from the Phase 2 trial for MT-401 as a treatment option for Acute myeloid leukemia (AML) in the post-transplant setting. No dose-limiting toxicities, cytokine release syndrome, or neurotoxicity were observed. 1 MRD+ patient became MRD- after infusion … Full story available on Benzinga.com

Benzinga | February 17, 2022

Marker Therapeutics Announces Clinical Program Updates and Pipeline Expansion

Results from safety lead-in stage of Marker’s Phase 2 AML trial demonstrate that MT-401 was well-tolerated, eliminated measurable residual disease (MRD) in one MRD+ patient and induced epitope spreading New T cell manufacturing process for MT-401 and other product candidates designed to improve potency, increase antigen specificity and diversity and significantly reduce manufacturing time Company announces clinical updates, including plans to file additional INDs by year end, with clinical trial

Yahoo | February 16, 2022

Marker Therapeutics to Host Clinical Program Update Conference Call and Webcast on Wednesday, February 16, 2022

HOUSTON, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that it will host a conference call and webcast on Wednesday, February 16, 2022 at 5:00 p.m. EST to provide an update on the Company’s clinical programs, manufacturing processes and pipeline. The webcas

Yahoo | February 8, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Good morning, investor!

William White on InvestorPlace | January 21, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Good morning, trader!

William White on InvestorPlace | January 20, 2022

Read More 'MRKR' Stories Here

MRKR Price Returns

1-mo -2.86%
3-mo -8.50%
6-mo N/A
1-year -87.41%
3-year -94.18%
5-year -90.91%
YTD -64.22%
2021 -34.47%
2020 -49.65%
2019 -48.11%
2018 41.58%
2017 1.03%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9603 seconds.